on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ruxolitinib under the National Health Act 1953, section 85 for patients at least 18 years of age with polycythemia vera.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ruxolitinib.
Authority applications
Applying for initial treatment
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Applications for initial authority approval to prescribe PBS-subsidised ruxolitinib to treat polycythemia vera can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed polycythemia vera - ruxolitinib - initial authority application
- relevant attachments.
Applications for balance of initial treatment (up to 48 weeks) can be made in real time using the Online PBS Authorities system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.
Applying for continuing treatment
Applying for the first continuing treatment
Applications for the first continuing authority approval to prescribe PBS-subsidised ruxolitinib to treat polycythemia vera can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for subsequent continuing treatment
Applications for subsequent continuing authority approval to prescribe PBS-subsidised ruxolitinib to treat polycythemia vera can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.